27m
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results